Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Expression Patterns of Xenobiotic-Metabolizing Enzymes in Tumor and Adjacent Normal Mucosa Tissues among Patients with Colorectal Cancer: The ColoCare Study
Ist Teil von
Cancer epidemiology, biomarkers & prevention, 2020-02, Vol.29 (2), p.460-469
Ort / Verlag
United States
Erscheinungsjahr
2020
Link zum Volltext
Quelle
MEDLINE
Beschreibungen/Notizen
Xenobiotic-metabolizing enzymes (XME) play a critical role in the activation and detoxification of several carcinogens. However, the role of XMEs in colorectal carcinogenesis is unclear.
We investigated the expression of XMEs in human colorectal tissues among patients with stage I-IV colorectal cancer (
= 71) from the ColoCare Study. Transcriptomic profiling using paired colorectal tumor and adjacent normal mucosa tissues of XMEs (
,
, and
) by RNA microarray was compared using Wilcoxon rank-sum tests. We assessed associations between clinicopathologic, dietary, and lifestyle factors and XME expression with linear regression models.
, and
were all statistically significantly downregulated in colorectal tumor relative to normal mucosa tissues (all
≤ 0.03). Women had significantly higher expression of
in normal tissues compared with men (β = 0.37,
= 0.02). By tumor site,
expression was lower in normal mucosa among patients with rectal cancer versus colon cancer cases (β = -0.21,
= 0.0005). Smokers demonstrated higher
expression levels in normal mucosa (β = 0.17,
= 0.02) when compared with nonsmokers. Individuals who used NSAIDs had higher
tumor expression compared with non-NSAID users (β = 0.17,
= 0.03). Higher consumption of cooked vegetables (>1×/week) was associated with higher
expression in colorectal tumor tissues (β = 0.14,
= 0.007).
XMEs have lower expression in colorectal tumor relative to normal mucosa tissues and may modify colorectal carcinogenesis via associations with clinicopathologic, lifestyle, and dietary factors.
Better understanding into the role of drug-metabolizing enzymes in colorectal cancer may reveal biological differences that contribute to cancer development, as well as treatment response, leading to clinical implications in colorectal cancer prevention and management.